The pharmaceutical company AstraZeneca has offered about $10 billion to buy Biotech Katsav Pharmaceuticals, the Wall Street Journal writes. The British manufacturer is willing to pay $124 per share, while Katsav's current market value is estimated at $6.6 billion. The deal will allow AstraZeneca to expand its portfolio of drugs to treat rare diseases, metabolic disorders and severe obesity.

The pharmaceutical company AstraZeneca has offered about $10 billion to buy Biotech Katsav Pharmaceuticals, the Wall Street Journal writes. The British manufacturer is willing to pay $124 per share, while Katsav's current market value is estimated at $6.6 billion. The deal will allow AstraZeneca to expand its portfolio of drugs to treat rare diseases, metabolic disorders and severe obesity.